

1 **Usability, acceptability and cost of the SD BIOLINE Ov16 rapid**
2 **diagnostic test for onchocerciasis surveillance in endemic**
3 **communities in the middle belt of Ghana**

4 Kenneth Bentum Otabil*^{1,2}, María-Gloria Basáñez³, Ameyaa Elizabeth⁴, Michael Oppong⁴, Prince
5 Mensah⁴, Richmond Gyasi-Ampofo⁴, Emmanuel John Bart-Plange^{1,4}, Theophilus Nti Babae¹,
6 Lydia Datsa⁵, Andrews Agyapong Boakye⁶, Michael Tawiah Yeboah⁷, Prince Nyarko¹, Prince
7 Charles Kudzordzi¹, Anabel Acheampong¹, Edwina Twum Blay¹, Henk D.F.H. Schallig⁸, Robert
8 Colebunders⁹

9 ¹*Consortium for Neglected Tropical Diseases and One Health, Centre for Research in Applied*
10 *Biology, School of Sciences, University of Energy and Natural Resources, Sunyani, Bono Region,*
11 *Ghana*

12 ²*Department of Biological Science, School of Sciences, University of Energy and Natural*
13 *Resources, Sunyani, Bono Region, Ghana*

14 ³*Department of Infectious Disease Epidemiology, MRC Centre for Global Infectious Disease*
15 *Analysis (MRC GIDA), and London Centre for Neglected Tropical Disease Research, School of*
16 *Public Health, Imperial College London, London, UK*

17 ⁴*Department of Medical Laboratory Science, School of Sciences, University of Energy and*
18 *Natural Resources, Sunyani, Bono Region, Ghana*

19 ⁵*Deo Gratias Medical Laboratories, Sunyani, Bono Region, Ghana*

20 ⁶*Kintampo Health Research Centre, Kintampo, Bono Region, Ghana*

21 ⁷*Ghana Health Service, Regional Neglected Tropical Diseases (RNTD) Office, Regional Health*
22 *Directorate, Sunyani, Bono Region, Ghana*

23 ⁸*Academic Medical Centre, Department of Medical Microbiology, Experimental Parasitology*
24 *Unit, Amsterdam University Medical Centres Amsterdam, The Netherlands*

25 ⁹*Global Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp,*
26 *Belgium*

27 ***Corresponding Author: Email: kenneth.otabil@uenr.edu.gh Tel: +233209164671**

28

29 **Short Title: Ov16 rapid diagnostic test for onchocerciasis surveillance in Ghana**

30

31 **Abstract**

32 **Background**

33 Previous studies in the Bono Region (middle belt) of Ghana have reported persistent
34 *Onchocerca volvulus* infection and associated morbidities after nearly three decades of
35 ivermectin treatment. This study aimed to assess the usability, acceptability and cost of the
36 Ov16 SD BIOLINE rapid diagnostic test (Ov16 RDT) in onchocerciasis surveillance activities in the
37 middle belt of Ghana.

38 **Methodology**

39 A cross-sectional study was conducted in 6 endemic communities in the Tain District and
40 Wenchi Municipality. A total of 254 individuals (54% females; median age (range)=31 (5–83)
41 years), agreed to participate in Ov16 RDT (100%), skin-snip microscopy (37%) and nodule
42 palpation (100%). Post-test interviews were conducted for all 94 participants tested by all three
43 diagnostics. A cost analysis based on testing 400 people was performed.

44 **Principal findings**

45 Ov16 seroprevalence was 23.6% (60/254, 95%CI=18.8%–29.2%); microfilarial prevalence 11.7%
46 (11/94, 95%CI = 6.7%–19.8%) and nodule prevalence 5.5% (14/254, 95%CI=3.3%–9.0%). The
47 proportion of Ov16 seropositive females (43/136, 31.6%) was twice that of males (17/117,
48 14.5%). Among 5–9-year-olds, Ov16 seroprevalence was 11.1% (3/27), microfilarial prevalence
49 23.1% (3/13) and nodule prevalence 3.7% (1/27). For the 94 participants with all three tests,
50 there was no association between the results of Ov16 RDT, skin-snip microscopy and/or nodule
51 palpation. Most participants and technicians preferred Ov16 RDT because of being less painful
52 and invasive, easier to use and faster. Had 400 participants been tested, the total cost per
53 individual would be US\$24 (Ov16 RDT) and US\$74 (skin-snip microscopy).

54 **Conclusions**

55 Ov16 RDT is more acceptable and affordable (a third of the cost) compared to skin-snipping for
56 surveillance activities in transmission hotspots in Ghana.

57 **Keywords:** Onchocerciasis, Ov16 seroprevalence, microfilaridermia, nodule palpation,
58 ivermectin, Ghana

59 **Author summary**

60 Onchocerciasis (River blindness) is a neglected tropical disease targeted by the World Health
61 Organization for elimination of transmission in 12 endemic countries by 2030. There is a need
62 for field-friendly, acceptable and affordable tools to monitor progress towards elimination. In
63 Ghana, the SD BIOLINE Ov16 rapid diagnostic test (Ov16 RDT) has been used in several
64 epidemiological surveys, but its usability, acceptability and cost have not been assessed. We
65 studied 6 endemic communities with persistent infection after nearly three decades of
66 ivermectin treatment. The prevalence of seropositivity by Ov16 RDT was twice the prevalence
67 of skin-snip microscopy positivity and four times the prevalence of nodule-palpation positivity.
68 For the individuals tested by all three diagnostics, we found no agreement between the results
69 of Ov16 RDT and skin-snip microscopy (and/or nodule palpation), likely owing to the long-term
70 treatment in the study area. The Ov 16 RDT was acceptable to both study participants and
71 technicians because it was less painful and invasive, and yielded results more quickly. The cost
72 of skin-snip microscopy would be thrice that of Ov16 RDT when testing 400 individuals. Ov16
73 RDT is more acceptable and less costly than skin-snipping for surveillance activities in
74 transmission hotspots in Ghana.

75

76 Introduction

77 Onchocerciasis is a severely debilitating, vector-borne neglected tropical disease (NTD) caused
78 by infection with the filarial nematode *Onchocerca volvulus* and transmitted among humans by
79 the bites of *Simulium* blackflies. Although the great majority (99%) of the cases are found in
80 sub-Saharan Africa (SSA), the infection also occurs in Yemen and in two (Venezuela and
81 Brazil).out of the six original endemic countries in Latin America [1]. In 2017, it was estimated
82 that at least 220 million people required preventive chemotherapy against onchocerciasis, and
83 according to the Global Burden of Disease (GBD) Study for that year, 14.6 million of those
84 infected had skin disease and 1.15 million had vision loss [2]. In 2019, the GBD Study estimated
85 that 19.1 (95% Uncertainty Interval, UI = 17.2–20.9) million people were infected, and that the
86 disease was responsible for 1.23 (95%UI = 0.765–1.82) million disability-adjusted life-years
87 (DALYs) [3]. Preventive chemotherapy relies on mass drug administration (MDA) delivered, in
88 Africa, as community-directed treatment with ivermectin (CDTI), predominantly annually, but in
89 several foci of some countries (such as Ethiopia, Ghana, Nigeria, Togo and Uganda), also 6-
90 monthly (biannually). Ivermectin is mainly microfilaricidal, and therefore CDTI programmes are
91 typically prolonged, partly due to the long lifespan of adult *O. volvulus* [4]. Elimination
92 (interruption) of transmission (EOT) has been reported for some foci of Mali, Senegal, Nigeria
93 and Sudan, without vector control [5].

94 In consequence, the World Health Organization (WHO) 2021–2030 NTD roadmap has proposed
95 that 12 endemic countries be verified for EOT of onchocerciasis by 2030 [6]. The WHO has
96 delineated three distinct phases in onchocerciasis elimination programmes: I) the treatment
97 phase with CDTI, during which monitoring and evaluation are conducted periodically to

98 ascertain progress towards transmission suppression and ultimately interruption; II) the post-
99 treatment surveillance (PTS) phase, during which CDTI is no longer delivered but indicators of
100 exposure and transmission are evaluated to confirm that EOT has been reached, and III) the
101 post-elimination surveillance (PES) phase, to alert of potential resurgence of transmission or re-
102 introduction of infection [7]. These distinct phases require different diagnostic tools that allow
103 transitioning from one to the next. During phase I, and until Stop-MDA surveys are conducted,
104 the gold standard for parasitological diagnosis and calculation of epidemiological indicators
105 (microfilarial prevalence and load), has been the detection and enumeration of *O. volvulus*
106 microfilariae by the so-called skin-snip microscopy method [8]. Skin-snip microscopy is highly
107 specific provided that microfilarial morphometric characteristics are assessed, and able to
108 detect active infection (as microfilariae are the embryonic progeny of reproductively active
109 adult worms), but its sensitivity (based on two snips) decreases as microfilarial prevalence and
110 load declines due to CDTI [9]. The procedure is also mildly invasive and resource-intensive, and
111 its acceptability diminishes in communities where decades of skin-snipping have occurred [10].

112 Skin-snip Polymerase Chain Reaction (PCR) has been suggested to circumvent the problem of
113 low sensitivity posed by dwindling skin microfilarial loads, to confirm the infection status of
114 Ov16-seropositive children, or when species-specific identification of microfilariae may be
115 necessary [11]. However, it is not practical for large-scale community surveillance in SSA
116 because it is expensive to purchase and operate and requires highly-skilled personnel.
117 Serological, enzyme-linked immunosorbent assay (ELISA) tests based on the detection and
118 quantification of IgG antibodies to the *O. volvulus* Ov16 recombinant antigen have shown, in
119 longitudinal human and chimpanzee studies, that Ov16 seropositivity may precede skin-snip

120 positivity, providing a marker of exposure to early infection stages [12]. Other studies, also in
121 chimpanzees, have indicated that Ov16 (IgG4) seroconversion coincides with the onset of
122 patency (detectable skin microfilariae) [13], but as its duration may exceed that of patent
123 infection, Ov16 seropositivity may not yield a useful marker of active infection. Besides, ELISA-
124 based serological tests also pose challenges including the need for laboratory analysis and the
125 lack of a standardized, commercially-available Ov16 ELISA test, resulting in marked inter-
126 laboratory variation [14]. A field-friendly, rapid diagnostic test (RDT) with the potential for
127 integration into current onchocerciasis surveillance activities in endemic countries, was
128 developed and made commercially available (SD BIOLINE Onchocerciasis IgG4 rapid test)
129 [14,15]. The performance of this Ov16 RDT has been evaluated in the field and current research
130 priorities focus on operational and implementation research to demonstrate its usefulness,
131 particularly in communities with low infection prevalence as a result of many years of CDTI [16].

132 In Ghana, ivermectin MDA has been implemented for more than 30 years, having started in the
133 late 1980s [17]. In 2009, a nationwide rapid epidemiological mapping of onchocerciasis (REMO)
134 evaluation was conducted to provide updated information on the distribution of the disease.
135 Areas with an infection (palpable nodule) prevalence in adult male samples above 20%, were
136 allocated to a biannual treatment frequency, also considering a buffer zone of 20 km around
137 these CDTI priority areas [18]. Forty-four districts were classified as meso- and hyperendemic
138 and have received biannual MDA since 2010. Forty-one districts, which were re-classified as of
139 low endemicity and were already on MDA before the REMO exercise, continued to receive
140 annual MDA. From 2015 to 2020, efforts were intensified to accelerate the shift from
141 onchocerciasis control to EOT. An operational threshold of microfilarial prevalence <1% was

142 adopted, the implementation unit changed from community to sub-district, and the
143 geographical and (reported) therapeutic coverage increased substantially. In 2017, an impact
144 assessment survey was carried out using Ov16 serology in children aged <10 years and skin-snip
145 microscopy in adults aged ≥ 20 years [19]. Together with historical data collected by the
146 Onchocerciasis Control Programme in West Africa (OCP), the impact assessment helped the
147 national NTD Programme to formulate strategies to reach EOT. Delineation epidemiological
148 surveys were conducted in 50 hypoendemic districts that had never received ivermectin (not
149 having been previously prioritized for control but in need of re-assessment for elimination), and
150 treatment strategies and management decisions were redefined [18]. Currently, 137 districts
151 require or are under biannual CDTI [19].

152 Previous studies in the Bono region of Ghana, in which some communities had been under
153 biannual CDTI since 2010, revealed that *O. volvulus* infection and associated cutaneous and
154 ocular morbidities persisted despite 27 years of treatment [19,20], and that despite high levels
155 of reported coverage [20], treatment adherence was relatively poor [21]. Although such
156 communities may not be ready to move from the treatment phase to Stop-MDA surveys, or
157 may require alternative interventions to accelerate progress [22] it is important to understand
158 the role of different diagnostics for surveillance activities.


159 As Ghana transits from the treatment phase to the next stages of the EOT pathway in some
160 endemic areas, and to evaluate progress towards suppression and interruption of transmission,
161 the suitability of current diagnostic tools to accompany such transition needs to be ascertained.
162 Whilst studies from other countries have investigated the acceptability, usability and cost of the

163 Ov16 RDT [10], no such study has been conducted in Ghana. Therefore, this study aimed to
164 assess the feasibility of integrating Ov16 RDT into onchocerciasis surveillance activities in Ghana
165 based on diagnostic attributes, technician and community acceptability, usability and cost.

166 **Materials and methods**

167 **Study area**

168 The study was performed in six communities, namely, four communities in the Tain District
169 (Abekwai 2, Abekwai 3, Attakrom and Kokomba) and two communities in the Wenchi
170 Municipality (Blibor and Jonnykrom/Adamakrom), in the Bono Region of Ghana. Fig 1 shows the
171 locations of the study villages. The communities were selected based on the following criteria
172 informed by previous studies [19,20]: i) they had persistent endemicity for *O. volvulus* infection,
173 albeit with relatively low prevalence; ii) they had received ivermectin MDA for at least 20 years
174 and biannual CDTI for about 10, and iii) they were situated close to fast-flowing rivers (the
175 Subin, the Tain, or their tributaries) where the blackfly vectors breed.



176
177 **Fig 1. Map of study communities in the Tain District and Wenchi Municipality, Bono Region,**

178 **Ghana.** The light pink area to the right of the study area represents the Nkoranza North District.

179
180 **Study design and recruitment**

181 This was a cross-sectional study, using both quantitative and qualitative approaches. Upon
182 entry into the communities, the research team first met the chief and opinion leaders to explain
183 the purpose, design, and procedures of the study. Once the community leaders agreed to
184 participate and a date for the survey was decided, announcements were made via ‘gong-gong’
185 beaters and/or information centres to request community members to gather at a specific
186 point in the village on the day. On the set day, the study was explained to the residents, and a

187 total of 254 individuals aged ≥ 5 years agreed to participate in some or all components of the
188 study, namely, a sociodemographic and health history questionnaire, Ov16 RDT testing (SD
189 BIOLINE Onchocerciasis IgG4 Rapid Test), two skin-snip biopsies for microscopy, nodule
190 palpation, and a post-test (exit) interview to assess their perceptions on the tests deployed and
191 to understand in which tests they would be willing to participate in future surveys. Participants
192 (or their parents/guardians) were asked to sign an informed consent form. Table 1 provides
193 details on the numbers recruited at each community, their sex composition and median age,
194 and the numbers examined for each onchocerciasis diagnostic. The study was conducted
195 between June and August 2021.

196 **Ethical considerations**

197 Ethical clearance for this study was obtained from the Committee for Human Research and
198 Ethics of the University of Energy and Natural Resources in Sunyani, Ghana, West Africa
199 (approval number: CHRE/AP/012/021). The study was explained to the parents/guardians and
200 school-age children in the local dialect (*Twi*). Informed written consent for children less than 18
201 years of age was given by their parents/guardians. Children gave oral assent to confirm their
202 willingness to participate in the study. Participants were informed that they had the option of
203 withdrawing at any stage of the study, without having to give any reasons, and without any
204 consequences following withdrawal.

205 **Sociodemographic questionnaire**

206 Participants were asked to state their sex and age, and respond to questions regarding whether
207 they had been born in the village (yes or no); their duration of residence in the community (<1

208 year or ≥ 1 year); whether they lived close to a stream (yes or no), visited a stream (yes or no)
209 and how often (every day or less than everyday), and their occupation (farming or non-
210 farming), with the aim to obtain information indicative of exposure to explore its association
211 with Ov16 status (positive or negative).

212 **Ov16 rapid diagnostic test**

213 The deployment of the IgG4-based SD BIOLINE rapid diagnostic test (Ov16 RDT) followed the
214 manufacturer's instructions (Standard Diagnostics, Yongin-si, Gyeonggi-do, South Korea) and
215 quality-assurance procedures. Briefly, the test cassette was labelled with the participant's
216 unique identification number. A finger of the participant was selected, cleaned with an alcohol
217 swab and pricked with the lancet provided with the kit. The blood was then collected using a
218 capillary tube and the blood was placed in the specimen well of the cassette. Four drops of
219 assay diluent were also placed in the assay diluent well. RDT results were read after 20 minutes
220 [10]. The product insert for the Ov16 RDT states that, compared to skin-snip microscopy as the
221 gold standard, its sensitivity is 81.1% (95%CI = 70.7%–88.4%) and its specificity is 99.0% (95%CI
222 = 94.8%–99.8%) using whole blood [10].

223 **Skin-snip microscopy**

224 Skin snipping was performed as described in our previous studies [19,20]. Briefly, the left and
225 right iliac crests of each participant were disinfected using alcohol swabs. Holth corneoscleral
226 punches were used to take about 2mg of bloodless skin snips each from the left and right iliac
227 crests. The snips were placed separately in microtitre wells containing 100 μ l normal saline
228 (NaCl 0.85%) and incubated at room temperature for 24 hours. After this period, the incubation

229 medium was pipetted onto a microscope slide and examined using, firstly, a x10 and
230 subsequently a x40 objective lens. If microfilariae (mf) had emerged, the participant was
231 recorded as skin-snip positive.

232 **Nodule palpation**

233 All participants were examined for palpable nodules by trained members of the medical team
234 (including a doctor, nurse and laboratory technicians) with experience in detecting onchocercal
235 nodules (onchocercomas). Palpations were done on bony protuberances of the ribs, iliac crests,
236 sacrum and upper leg, but not at locations (neck, axillae, inguinal) typical for lymph nodes.
237 Nodules were defined as ‘suspected’ onchocercomas (i.e., not confirmed by dissection or
238 biopsy) which were firm, often flattened or bean-shaped, usually movable, non-tender and up
239 to several centimetres in diameter.

240 **Usability and acceptability of Ov16 RDT**

241 To assess the usability and acceptability of the RDT, all of the RDT technicians (n=9) who also
242 had experience in skin-snip microscopy, and community residents (n=94) who participated in all
243 three tests (RDT, skin-snip microscopy and nodule palpation) were interviewed (S1 Text). The
244 interview guide was developed along the themes of preference and reasons for preference by
245 participants and technicians regarding the use of Ov16 RDT for surveillance following [10]. The
246 interviews were recorded using an audio recorder on Android phones and transcribed
247 *verbatim*. Interview data were coded using content analysis based on key themes from the
248 semi-structured interviews as done in [10].

249 **Economic costs**

250 To evaluate the cost associated with the implementation of onchocerciasis surveillance
251 programmes in Ghana using Ov16 RDT and skin-snip microscopy, a costing analysis was done
252 based on 400 participants as the basis for our calculations to enable comparison of costs for
253 each test without the effect of the numbers actually tested in any given survey. Briefly, the
254 value of volunteers' time as well as the surveillance costs were computed using the 'ingredient'
255 approach, multiplying the input prices by the number of inputs used [23]. The major input
256 prices for this analysis were the cost of each: a) Ov16 RDT (US\$2.82 per cassette); b) Holth
257 corneoscleral punch (US\$423.5 per punch), and c) optical microscope (US\$1,694). In addition,
258 costs were captured for all activities conducted during the surveillance activity, including
259 training, fieldwork and data reporting. Fieldwork cost categories were further split into
260 transport and lodging, supplies, devices and instruments, and labour. An exchange rate of
261 GHS7.08 (cedis) per US\$ was used in agreement with the rate for 2021.

262 **Data analysis**

263 Data were entered in purposely designed MS Excel spreadsheets (one for the epidemiology
264 results and another for the cost menus). Analyses were conducted using Jamovi Desktop
265 (version 2.3.19) and GraphPad Prism 8 for macOS (version 8.2.1). Two x two contingency tables
266 for the (dichotomous) responses to the sociodemographic questionnaire and Ov16 status
267 (positive or negative) were analysed using (two-tailed) Chi-squared test (without Yates
268 continuity correction as all frequencies were greater than 1) [24]. Two x two tables for
269 concordance were analysed for those participants who underwent all three tests, firstly
270 comparing Ov16 with skin-snip results and secondly, comparing Ov16 with skin-snip and/or

271 nodule-palpation results combined as ‘Oncho’ status. For such analyses we report the values of
272 the following parameters: i) kappa statistic and its 95% confidence interval (95%CI), a measure
273 of agreement between the results of two alternative techniques of categorical assessment that
274 takes into account whether the agreement is occurring by chance; ii) the overall proportion of
275 agreement (p_0); iii) the proportion of positive agreement (p_{pos}); iv) the proportion of negative
276 agreement (p_{neg}), v) the McNemar’s Chi-squared statistic with its P-value; and vi) the sensitivity,
277 specificity, positive predictive value (PPV) and negative predictive value (NPV) [25,26]. When
278 reporting proportions, 95%CIs were calculated using the Wilson score method [27]. Proportions
279 were compared by assessing their 95%CIs or by using the z-statistic where appropriate (non-
280 paired data), in which case asymptotic 95%CIs are reported [24]. The significance level for all
281 analyses was set at 0.05. A sample size was not calculated a priori for the study sites; our
282 sample is a convenience sample with an average sample size of 12% (range=5%–33%) of the
283 community populations (Table 1). The number of participants recruited per village (at least 30
284 participants per community) is consistent with the usual number of individuals per village
285 recruited for onchocerciasis epidemiological studies [28].

286 **Results**

287 Of the total of 254 individuals, there were 253 with recorded sex, consisting of 136 (53.8%)
288 females and 117 (46.3%) males. Age was recorded for 242 individuals, with a median age of 31
289 (range=5–83) years (Table 1). Respectively, 254 (100%), 94 (37%) and 254 (100%) individuals
290 agreed to participate in the Ov16 RDT, skin-snip microscopy and nodule palpation tests.

291 Therefore 94 participants underwent all three tests. The proportion of the population for
292 whom microfilaridermia was assessed ranged from 26% to 47%.

293 Of the 254 individuals tested for Ov16 RDT, 60 (23.6%, 95%CI = 18.8 %–29.2%) were
294 seropositive, compared to 11 (11.7%, 95%CI = 6.7%–19.8%) microfilaria-positive individuals out
295 of the 94 with skin-snip results (z-value = 2.5; P-value = 0.0143). For palpable nodules, 14 out of
296 254 individuals examined were positive (5.5%, 95%CI = 3.3%–9.0%). The prevalence of palpable
297 nodules was only marginally significantly different from that of microfilaridermia (z-value = 2, P-
298 value = 0.0471), but highly significantly different from that of Ov16 (z-value = 5.8, P-value
299 <0.0001).

300

301 **Table 1. Characteristics of the population sampled for each study community in the Bono**
 302 **region of Ghana.**

Community	Recruited/ Population (%)	Sex [†]		Median age [‡] (range) (Years)	No. Tested		
		Females (%)	Males (%)		Ov16 RDT (%)	Skin snip (%)	Nodules (%)
Tain District							
Abekwai 2	30/150 (20.0%)	17 (56.7%)	13 (43.3%)	22 (5–61)	30 (100%)	11 (36.7%)	30 (100%)
Abekwai 3	60/700 (8.6%)	29 (48.3%)	31 (51.7%)	30 (5–83)	60 (100%)	23 (38.3%)	60 (100%)
Attakrom	41/800 (5.1%)	21 (52.5%)	19 [†] (47.5%)	47 (9–80)	41 (100%)	15 (36.6%)	41 (100%)
Kokomba	40/120 (33.3%)	24 (60.0%)	16 (40.0%)	25 (7–60)	40 (100%)	16 (40.0%)	40 (100%)
Wenchi Municipality							
Blibor	47/240 (19.6%)	18 (38.3%)	29 (61.7%)	27 (7–80)	47 (100%)	12 (25.5%)	47 (100%)
Johnykrom/ Adamakrom	36/170 (21.2%)	27 (75.0%)	9 (25.0%)	41 (6–72)	36 (100%)	17 (47.2%)	36 (100%)
Total							
	254/2,180 (11.7%)	136 (53.8%)	117 (46.3%)	31 (5–83)	254 (100%)	94 (37.0%)	254 (100%)

303 [†]Of the 254 participants, sex was recorded for 253 (sex missing for one participant in Attakrom).

304 [‡]Age was recorded for 242 participants (age missing for one participant in each of Abekwai 2
 305 and Abekwai 3, four participants in Attakrom, three in Kokomba and three in Johnykrom).

306

307 The distribution of Ov16 status based on (dichotomised) sociodemographic information and
308 infection status is presented in Table 2. The following variables were statistically significantly
309 associated with Ov16 status (positive or negative): sex (female or male), age (<30 or ≥30
310 years), occupation (farming or not farming) and palpable nodules (positive or negative).
311 Microfilaridermia and Ov16 statuses were not associated. Among seropositives, the
312 proportion of females (71.7%, 95%CI = 59.2%–81.5%) was statistically significantly higher than
313 that of males (28.3%, 95%CI = 18.5%–40.8%); the proportion of those aged ≥30 years (76.4%,
314 95%CI = 63.7%–85.6%) was higher than those aged <30 (23.6%, 95%CI = 14.4%–36.4%), and
315 the proportion of farmers (84.8%, 95%CI = 73.5%–91.8%) was higher than that of non-farmers
316 (15.3%, 95%CI = 8.2%–26.5%). The proportion of those without microfilaridermia (89.5%,
317 95%CI = 68.6%–97.1%) was higher than of those with a positive skin snip (10.5%, 95%CI =
318 2.9%–31.4%), and the proportion of those without palpable nodules (88.3%, 95%CI = 77.8%–
319 94.2%) was higher than of those presenting onchocercomas (11.7%, 95%CI = 5.8%–22.2%).

320 Also among the Ov16 seropositives, the proportion of those living close to streams (81.7%,
321 95%CI = 70.1%–89.4%) was higher than that of those who did not live close (18.3%, 95%CI =
322 10.6%–29.9%), and the proportion of those visiting streams (71.4%, 95%CI = 58.5%–81.6%)
323 was higher than that of those who did not visit streams (28.6%, 95%CI = 18.4%–41.5%).
324 However, the proportion of those visiting streams daily was lower (25.7%, 95%CI = 14.2%–
325 42.1%) than of those visiting less frequently (74.3%, 95%CI = 57.9%–85.8%).

326 The two participants who were both Ov16 and skin-snip positive were females who had taken
327 ivermectin in the previous year (2019). Of the 17 participants who were Ov16 positive but

328 skin-snip negative, 13 (76.5%) were female and all 17 had taken ivermectin in the previous
329 year.

330 **Table 2. Sociodemographic information, infection status and Ov16 RDT status of participants.**

Description [No. participants for whom data were collected]	No. Ov16 Negative (%)	No. Ov16 Positive (%)	χ^2 statistic (P-value [†])
Sex [253]			
Female	93 (36.8%)	43 (17.0%)	10.15 (0.0014)
Male	100 (39.5%)	17 (6.7%)	
Age [242]			
<30 years	101 (41.7%)	13 (5.4%)	15.74 (0.0001)
≥30 years	86 (35.5%)	42 (17.4%)	
Duration of stay in the village [244]			
Born in village and <1 year	92 (37.7%)	23 (9.4%)	0.57 (0.4490)
≥1 year	98 (40.2%)	31 (12.7%)	
Proximity to stream [254]			
Yes	166 (65.4%)	49 (19.3%)	0.54 (0.4639)
No	28 (11.0%)	11 (4.3%)	
Visit stream [236]			
Yes	133 (56.4%)	40 (16.9%)	0.13 (0.7162)
No	47 (19.9%)	16 (6.8%)	
Frequency visiting stream [170]			
Everyday	47 (27.6%)	9 (5.3%)	1.04 (0.3073)
<Everyday	88 (51.8%)	26 (15.3%)	
Occupation [251]			
Farming	127 (50.6%)	50 (19.9%)	7.51 (0.0061)
Non-farming	65 (25.9%)	9 (3.6%)	

Presence of skin microfilariae [94]			
Yes	9 (9.6%)	2 (2.1%)	0.03
No	66 (70.2%)	17 (18.1%)	(0.8583)
Presence of palpable nodules [254]			
Yes	7 (2.8%)	7 (2.8%)	5.71
No	187 (73.6%)	53 (20.9%)	(0.0168)

331 [†]P-value for the 2-tailed Chi-squared statistic for 2 x 2 contingency tables.

332

333 **Prevalence by age and sex of test positivity for Ov16 RDT, skin-snip microscopy and nodule**
 334 **palpation**

335 Table 3 presents the results of the age and sex distribution of Ov16 RDT, skin-snip and palpable
 336 nodule positivity. The prevalence of the three indicators tended to be higher among those aged
 337 ≥ 30 years, but confidence intervals were wide. The seroprevalence in this age group was 32.8%
 338 (95%CI = 25.3%–41.3%). In the 5–9 age group, 3/27 children (11.1%, 95%CI = 3.9%–28.1%) were
 339 Ov16 positive, 3/13 children (23.1%, 95%CI = 8.2%–50.3%) skin-snip positive, and 1/27 (3.7%,
 340 95%CI = 0.7%–18.3%) nodule positive. The results by year of age for Ov16 were: 0/4 for 5-year-
 341 olds, 0/5 for 6-year-olds, 1 (boy)/9 for 7-year-olds, 0/3 for 8-year-olds and 2 (one boy and one
 342 girl)/6 for 9-year-olds. For skin-snip positivity, the results were: 0/3 for 5-year olds, 1 (boy)/4 for
 343 6-year olds, 2 (one boy and one girl)/3 for 7-year olds, 0/2 for 8-year olds and 0/1 and 9-year
 344 olds. The nodule-positive child (boy) was aged 5. The prevalence of Ov16 seropositivity among
 345 females (31.6%) was twice as high as that among males (14.5%), and this difference was
 346 statistically significant (z-value = 3.2, P-value = 0.0014). Fig 2 presents Ov16 seropositivity by
 347 age group and sex for the 242 participants with recorded age.


348 **Table 3. Age and sex distribution of test positivity for Ov16 RDT, skin-snip microscopy and nodule palpation for *Onchocerca***
 349 ***volvulus* in the study communities, Bono Region, Ghana.**

Category	Positivity by Ov16 RDT n +ve/N examined (%) [95% CI]	Positivity by skin-snip n +ve/N examined (%) [95% CI]	Positivity by nodule palpation n +ve/N examined (%) [95% CI]
Age [†] (years)			
5–9	3/27 (11.1%) [3.9% – 28.1%]	3/13 (23.1%) [8.2% – 50.3%]	1/27 (3.7%) [0.7% – 18.3%]
10–19	2/36 (5.6%) [1.5% – 18.1%]	2/15 (13.3%) [3.7% – 37.9%]	2/36 (5.6%) [1.5% – 18.1%]
20–29	8/51 (15.7%) [8.2% – 28.0%]	2/16 (12.5%) [3.5% – 36.0%]	1/51 (2.0%) [0.4% – 10.3%]
30–39	11/32 (34.4%) [20.4% – 51.7%]	3/10 (30.0%) [10.8% – 60.3%]	2/32 (6.3%) [1.7% – 20.2%]
≥40	31/96 (32.3%) [23.8% – 42.2%]	1/37 (2.7%) [0.5% – 13.8%]	8/96 (8.3%) [4.3% – 15.6%]
Total	55/242 (22.7%) [17.9% – 28.4%]	11/91 (12.1%) [6.9% – 20.4%]	14/242 (5.8%) [3.5% – 9.5%]
Sex [‡]			
Female	43/136 (31.6%) [24.4% – 39.9%]	6/53 (11.3%) [5.3% – 22.6%]	6/136 (4.4%) [2.0% – 9.3%]
Male	17/117 (14.5%) [9.3% – 22.0%]	5/41 (12.2%) [5.3% – 25.5%]	8/117 (6.8%) [3.5% – 12.9%]
Total	60/253 (23.7%) [18.9% – 29.3%]	11/94 (11.7%) [6.7% – 19.8%]	14/253 (5.5%) [3.3% – 9.1%]

350 [†] Age was recorded for 242 of the 254 participants. [‡] Sex was recorded for 253 participants.

351

352



353

354 **Fig 2. Ov16 seropositivity by age group and sex among 242 participants with recorded age.**

355 Hatched bars: Females, black bars: males, error bars: 95% confidence intervals.

356

357 **Concordance between tests**

358 Table 4 presents the results of the 2 x 2 concordance test between the Ov16 RDT assay and

359 skin-snip microscopy for the 94 participants from whom skin biopsies were taken, as well as

360 the results of Ov16 RDT compared with the 'Oncho' status of the same participants

361 (combining the results of skin-snip microscopy and nodule palpation). In both cases, the

362 value of kappa is not statistically different from zero, indicating poor agreement between

363 tests after correcting for chance agreement [26]. The McNemar's Chi-squared statistics and

364 corresponding P-values indicate that the results of the tests are not significantly associated,

365 with a proportion of positive agreement between 13% and 18%, a proportion of negative

366 agreement of approximately 83%, and a proportion of overall agreement of roughly 70%.

367 The sensitivity of the Ov16 RDT was about 20% and its specificity of about 80% in

368 comparison to skin-snip microscopy or skin-snip and/or nodule palpation.

369 **Table 4. Two x two concordance results for the comparison between Ov16 Rapid**
 370 **Diagnostic Test (RDT) vs. skin-snip microscopy (SS), and Ov16 RDT vs. ‘Oncho’ status (skin-**
 371 **snip and/or nodule palpation).**

	Ov16 RDT vs. Skin-snip microscopy			Ov16 RDT vs. ‘Oncho’ status		
	SS +ve	SS -ve	SS Total	Oncho +ve	Oncho -ve	Oncho Total
Ov16 +ve	2	17	19	3	16	19
Ov16 -ve	9	66	75	11	64	75
Ov16 Total	11	83	94	14	80	94
Concordance parameters						
<i>kappa</i>	0.018			0.0125		
[95% CI]	[0.0203 – 0.168]			[0.190 – 0.215]		
(P-value)	(0.4292)			(0.4511)		
p_0	72.3%			71.3%		
p_{pos}	13.3%			18.2%		
p_{neg}	83.5%			82.6%		
McNemar’s X^2 statistic	0.188			0.593		
(P-value)	(0.1698)			(0.4414)		
Sensitivity	18.2%			21.4%		
Specificity	79.5%			80.0%		
PPV	10.5%			15.8%		
NPV	88.0%			85.3%		

372 p_0 = Overall proportion of agreement; p_{pos} = Proportion of positive agreement;
 373 p_{neg} = Proportion of negative agreement; PPV = Positive predictive value; NPV = Negative
 374 predictive value.

375

376 **Acceptability of Ov16 RDT, skin-snip microscopy and nodule palpation**

377 The 94 individuals who participated in all three tests were interviewed after the
378 diagnostics were completed (exit questionnaire, S1 Text). The majority of the participants
379 (71/94 = 75.5%) preferred the Ov16 RDT to skin-snip microscopy for reasons including that
380 the Ov16 RDT procedure was less painful, less invasive and that they could see their results
381 in 30–40 minutes, rather than waiting until the next field visit to learn whether or not they
382 were ‘positive’:

383 *“This test (Ov16 RDT) is better! It is less painful than the one where you (health personnel)*
384 *‘cut the buttocks’ (skin snip)” (Female participant, Abekwai 2).*

385 *“I don’t normally see the need to participate in the test where you take some skin from my*
386 *buttocks. A lot of times, you (health personnel) just cut the skin and we don’t hear anything*
387 *about our results. I like this new one (Ov16 RDT) as I got to know my results immediately”*
388 *(Male participant, Abekwai 3).*

389 Despite the majority’s preference for Ov16 RDTs, 34% (32/94) remarked that they were
390 ‘okay’ with skin-snip microscopy and were willing to ‘endure’ the pain, as long as they
391 were convinced that undergoing the test would improve their health and wellbeing. This
392 proportion of respondents was in agreement with the 37% of the recruited individuals who
393 agreed to be skin-snipped (Table 1).

394 *“For me, I am okay if you (technician) cut skin on my buttocks (skin snip), as long as it will*
395 *help towards treating me early. The pain is only temporary, good health is what matters”*
396 *(Adult male, Attakrom).*

397 However, 20% (19/94) of participants detested the skin-snip method and stated that they
398 would not engage in any future surveys involving this method. The major reasons for this
399 included the painful nature of skin-snipping and its invasiveness. Some participants also
400 argued that they experienced itching, developed a rash or suffered from other allergic
401 reactions after they had been skin-snipped:

402 *“For me, I will run away if you (technician) come here again with that your scissors, it is too*
403 *painful” (Female participant, Johnykrom).*

404 Regarding the use of nodule palpation, 98% (92/94) of the study participants were ‘okay’
405 with it, with 18% (17/94) preferring to be examined for nodules by a person of the same
406 sex, and 2% (2/94) not being at all comfortable with being palpated for nodules due to
407 religious reasons:

408 *“As for me, I don’t like it when the female doctor is touching parts of my body as she will*
409 *see my nakedness” (Adult male, Blibor).*

410 **Usability and acceptability of Ov16 RDT among technicians in the study**

411 The study interviewed all nine technicians who performed the Ov16 RDTs and who were
412 also experienced in skin-snip microscopy, with 89% (8/9) preferring the former test over the
413 latter. The reasons for this included that it required less effort and training and met with
414 less resistance from the survey participants on the account of being less painful and less
415 invasive. The rapid turnaround time of the Ov16 RDT results (within 30–40 minutes from
416 sampling to results) as opposed to more than 24 hours for skin-snip microscopy further
417 increased the willingness of the community to take part in surveillance activities. The
418 technicians also liked the fact that children were able to participate in the serological
419 survey. Most of the technicians also indicated that they trusted the results from the Ov16

420 RDT as it tends to lend itself to fewer human errors. When prompted on the challenges with
421 the use of the Ov16 RDT, most technicians referred to the fact that being antibody-based,
422 the test could not differentiate between past and current infections. They therefore
423 advocated for both tests; first Ov16 RDT for indication to exposure, followed by
424 confirmation of active infection with skin-snip microscopy when necessary. Nevertheless, all
425 technicians remarked that they would prefer to use Ov16 RDTs in future surveillance
426 activities.

427 **Cost analysis for Ov16 RDT and skin-snip microscopy**


428 *Time considerations.* The training of nine technicians for the Ov16 RDT took a maximum of
429 two hours (120 minutes) in contrast to 14 days (6,720 minutes for an 8-hour daily schedule)
430 for the training of five technicians on skin-snip microscopy. The Ov16 RDT took
431 approximately 10 minutes to take a sample from each participant (labelling the cassette,
432 selecting, and cleaning a finger, pricking the finger and placing the blood and the assay
433 diluent in the cassette) and 30–40 minutes to get and communicate the results (20 minutes
434 to read the results from the cassette and 10–20 minutes to record such results and convey
435 them to participants). By contrast, skin-snip microscopy took about 30 minutes for sampling
436 from each participant (cleaning left and right iliac crests with alcohol swabs, taking the skin
437 snips with disinfected punches, placing the snips in labelled microtitre plate wells containing
438 incubation medium, recording participant details), 24 hours for the incubation of the snips
439 and about 20 minutes to pipette and observe the incubation medium under a microscope
440 under two magnifications, for a total of 24 hours and 50 minutes (1,490 minutes) to obtain
441 the results. A common concern was that the participants of skin-snip microscopy typically
442 never get to know their results or at best get to know them only during the next field visit,

443 which can take weeks or months. These have cost implications for both Ov16 RDT and skin-
444 snip microscopy tests.

445 *Cost considerations.* The total cost for the activities targeting 400 participants was estimated
446 at US\$32,156. The cost was apportioned to Ov16 RDT, skin-snip microscopy and shared cost.
447 The costs incurred for Ov16 RDT and skin-snip microscopy test and activities were US\$2,412
448 (7.5%) and US\$22,670 (70.5%), respectively. The shared cost incurred accounted for 22% of
449 the total cost of the study (US\$7,074). Within the total cost, 94.8% (US\$30,484)
450 corresponded to fieldwork cost, comprised of transport and lodging (72.0%), supplies,
451 devices and instruments (21.4%), and labour cost (1.4%). Training and reporting costs
452 accounted for 5.1% (US\$1,640) and 0.1% (US\$32) of the total cost, respectively. The total
453 cost per participant of the Ov16 RDT was US\$ 23.72 (US\$6.03 for test-specific costs and
454 US\$17.69 for shared costs); the cost of skin-snip microscopy was US\$74.36 (US\$56.67 for
455 test-specific costs and US\$17.69 for shared costs). The cost per participant of deploying
456 Ov16 RDT and skin-snip microscopy testing based on 400 participants and split by category
457 is presented in Fig 3.

458 Proportionally reducing costs according to the numbers tested in our study (254 for Ov16
459 RDT and 94 for skin-snip microscopy) and adjusting for fixed inputs, the total cost of the
460 activity was estimated at US\$24,708 for the 6 communities surveyed, with a net cost per
461 participant of US\$27 for Ov16 RDT and US\$207 for skin-snip microscopy, highlighting the
462 impact of the volume effect [10].

463



464

465 **Fig 3. Cost analysis per Ov16 rapid test (Ov16 RDT) and skin-snip microscopy for 400**

466 **individuals tested for each diagnostic.**

467 Discussion

468 This study aimed to determine the usability, acceptability and cost of the Ov16 RDT for
 469 onchocerciasis surveillance in endemic communities in the middle belt of Ghana,
 470 particularly in the Tain District and Wenchi Municipality where it has been reported that
 471 onchocerciasis persists after 27 years of ivermectin MDA [19,20]. The seroprevalence
 472 among study participants was 24%, the microfilarial prevalence was 12% and the nodule
 473 prevalence was 6%. Sex, age group, occupation and palpable nodule status were
 474 significantly associated with Ov16 status, whereas duration of stay in the village, living in
 475 proximity to a stream, visiting the stream, frequency of visiting the stream and skin-snip
 476 status were not (Table 2). Among the Ov16 seropositives, there was a significantly higher
 477 proportion of females, those aged 30 years or older, living near streams, visiting such

478 streams and engaged in farming. However, the proportions of those presenting skin
479 microfilariae or palpable nodules were significantly lower.

480 Since the study communities have received ivermectin MDA for nearly three decades,
481 those aged ≥ 30 years at the time of our study would have been exposed as children to
482 baseline levels of transmission. We have previously reported that the study area was
483 initially mesoendemic, with a baseline microfilarial prevalence of 41% to 48% [20]. This is
484 broadly in agreement with the 33% seroprevalence we found among those 30 years or
485 older. Of the 126 females sampled, more than half (61%) were aged ≥ 30 years, whereas of
486 the 116 males sampled, less than half (44%) belonged to this age group; nearly 100% of
487 those 30 years of age or older were farmers (76/77 females and 50/51 males).

488 As the blackfly vectors breed in fast-flowing rivers and streams [1], it is perhaps not
489 surprising that those living near or visiting such water bodies were more frequently
490 represented among seropositive individuals, but contrary to expectation the proportion of
491 those visiting streams daily was lower than that of those visiting less often. Farming can be
492 another activity that increases exposure to blackfly bites, and historically, agricultural
493 communities are known to have been highly endemic for onchocerciasis as farms are often
494 situated near rivers that provide water for crops [29]. As blackflies are outdoor and diurnal
495 biters, farmers working outdoors for several hours of the day may have an increased risk
496 of exposure. In the Tombel Health District, Southwest region of Cameroon, and after 15
497 years of CDTI, Nyagang et al. [30] reported higher onchocerciasis prevalence in those aged
498 more than 60 years, who were mostly farmers. The greatest prevalence of infection (2.1%)
499 was among farmers [30]. A study in Southwest Ethiopia, also after 15 years of CDTI,
500 reported that individuals aged ≥ 35 years had a microfilarial prevalence of 15.7% compared

501 to 1.4% in those aged 15–24-years (no children under 15 were examined), and that
502 approximately 60% of the participants were farmers, of whom 9% were microfilaria-
503 positive [31]. The authors stated that adults were engaged in outdoor activities, increasing
504 their exposure to blackfly bites [31].

505 Although Ov16 seroprevalence levels, particularly in the young, have been considered to
506 indicate exposure to infection, knowledge of the parasite stage(s) that elicit IgG4 antibody
507 seroconversion to the Ov16 antigen, as well as of the dynamics of seroconversion and
508 potential seroreversion or antibody decay under transmission interruption remains
509 outstanding. Willen et al. [32,33] reported, using data from Ghana, on the development of
510 an IgG-based immunoassay to quantify antibodies to *Simulium damnosum* sensu lato
511 saliva that, if combined with assays to detect past or current exposure to *O. volvulus* could
512 help to investigate exposure to blackfly bites and to the parasite.

513 In our study, Ov16, skin-snip and nodule positivity were generally higher among those
514 aged 30 years or older (with the exception of microfilarial prevalence, which was lowest in
515 those ≥ 40 years of age). Since only 94/254 (37%) of the participants agreed to be skin-
516 snipped, with complete data on age and sex for 91 of these, our results need to be
517 interpreted with caution. Notwithstanding our small sample sizes, 11%, 23% and 4% of the
518 5–9-year olds examined were positive for antibodies against Ov16, microfilaridermia and
519 onchocercomas, respectively (Table 3). As the nodule-positive child was aged 5 and the
520 pre-patent period (from infection to detectable microfilaridermia) of *O. volvulus* has been
521 estimated to range between 1 and 3 years [34], we can infer that this child became
522 infected when he was 3–4 years of age, underscoring the occurrence of ongoing
523 transmission in the study villages. Although Ov16 seroprevalence by age was generally

524 higher for females compared to males (with the exception of the 5–9-year age group),
525 sample sizes were small, leading to wide 95% CIs (Fig 2), precluding us from drawing firm
526 conclusions about sex- and age-specific exposure patterns.

527 The low positive agreement between Ov16 and skin-snip positivity is likely explained by
528 the fact that treatment leads to a reduction in skin microfilariae but antibodies to Ov16
529 may remain for much longer [10], with the levels of Ov16 and skin-snip positivity becoming
530 increasingly disassociated as treatment progresses.

531 The McNemar chi-square statistic showed no association between Ov16 RDT and skin-snip
532 microscopy (or ‘Oncho’ status when combining skin-snip microscopy and/or nodule
533 palpation), indicating that Ov16 RDT is not an appropriate tool for determination of active
534 infection trends in surveillance activities, for which, in any case, it was not designed.
535 However, given the relatively high level of negative agreement (83%–84%) and NPV (85%–
536 88%), it may be possible to use Ov16 RDT for screening (all ages), subsequently focusing on
537 those Ov16 positive for further testing with skin-snip microscopy and/or skin-snip PCR.
538 According to the RDT manufacturer, the test has 81% sensitivity and 99% specificity [10],
539 but likely due to long-term treatment in the study area, our estimated values were very
540 low (about 20% and 80%, respectively) (Table 4).

541 We acknowledge that the WHO guidelines for stopping MDA and verifying elimination of
542 transmission do not advocate the use of Ov16 serology to detect active infection or its use
543 in all ages, but rather in those under 10 years of age using ELISA, with a seropositivity
544 <0.1% at the upper 95% confidence bound in a sample of 2,000 children being taken as an
545 indication of transmission interruption [35]. Modelling studies have investigated the
546 applicability, to predict EOT outcomes, of this (and less stringent) threshold(s) and age

547 group(s) under different assumptions of exposure and regulation of parasite abundance
548 [36], and ongoing studies (some in Ghana) are being conducted to test such thresholds in
549 the field.

550 We found that conducting Ov16 RDT testing in all ages provided useful information
551 interpretable in the context of the duration of treatment in the area, as done by others in
552 Mali and Tanzania [37,38]. Our results also indicate that the study communities are not yet
553 at the point of commencing Stop-MDA surveys despite having received nearly three
554 decades of ivermectin MDA. However, since we did not sample 2,000 children aged less
555 than 10 years, our results are surrounded by considerable uncertainty. Despite this
556 uncertainty, we have documented persistence of *O. volvulus* infection and associated
557 clinical manifestations in the study area [19,20], and investigated factors influencing
558 treatment adherence which could partly explain such persistence [21]. Entomological
559 studies should also be undertaken in the study area to assess infection levels in simuliid
560 population samples.

561 Studies done in other African settings with long-term CDTI (using the Ov16 RDT with whole
562 blood) have reported, in the Ulanga district of Morogoro, Tanzania (an initially
563 hyperendemic area), seroprevalence levels of 14% (27/191) in those aged 6–10 years and
564 33% (26/79) in those aged 11–12 after more than 20 years of CDTI [39]. In a formerly
565 highly endemic area in the Mbam and Sanaga river valleys of Cameroon, Siewe Fodjo et al.
566 [40] found an Ov16 seropositivity of 47% (68/145) in Bilomo (Centre Region) and 52%
567 (13/25) in Kelleng (Littoral Region) among children aged 7–10 years after >13 years of
568 CDTI. A factor likely involved in the persistence of onchocerciasis in this area is the very
569 high (and perennial) biting rates of the blackfly vectors, as documented in other localities

570 of the Mbam and Sanaga river systems, both historically and recently [41,42]. As our study
571 area was originally mesoendemic, and annual biting rates in the region were of the order
572 of 3,000–4,000 per person [19], it would be advisable to update entomological studies in
573 the Tain District and Wenchi Municipality of Ghana to better understand the potential
574 contribution of blackfly abundance, species composition and transmission intensity to
575 persistent infection. A study in the Nkoranza North District (see Fig 1) documented highly
576 seasonal transmission, with monthly biting rates of approximately 800 in the peak
577 transmission season and 0–100 in other months of the year [43].

578 In terms of diagnostic test acceptability, most participants preferred the Ov16 RDT to skin-
579 snip microscopy and nodule palpation on account of its being less invasive, less painful and
580 more rapidly generating results that the participants could see *in situ*. These attributes of
581 the RDT could be capitalised upon to increase the willingness of the population to
582 participate in surveillance activities. Our findings are consistent with those of Dieye et al.
583 [10] in south-eastern Senegal, who reported a greater willingness of participants to take
584 part in onchocerciasis surveillance activities involving Ov16 RDT. Interestingly, the
585 participation rates in Ov16 RDT (99.7%) and skin-snip microscopy (32.7%) in the Senegal
586 study [10] are very similar to ours in Ghana (100% and 37%, respectively), suggesting that
587 about a third of the population might be willing to participate in skin-snipping surveys. As
588 endemic countries transit the path towards onchocerciasis EOT, it is increasingly important
589 that the surveillance tools used in control and elimination programmes are both effective
590 and acceptable. Residents of meso- and hyperendemic communities have typically had a
591 long history of MDA treatment and are, therefore, increasingly apathetic towards control
592 and surveillance activities, especially because the disease is no longer perceived as a major
593 public health problem in some areas.

594 As mentioned, about a third of the individuals taking part in the 'exit' interviews remarked
595 that although skin-snipping is painful, they would be willing to participate in future
596 parasitological surveys using skin-snip microscopy. This was partly due to the research
597 team members explaining to the participants the need for the test and the potential
598 benefits to their health outcomes. Thus, the influence of the surveillance staff on
599 participation rates should not be underestimated. The National Onchocerciasis Control
600 Programme could leverage this finding to tackle issues of growing apathy in endemic
601 communities.

602 The Ov16 RDT was also generally preferred among the technicians involved owing to its
603 being relatively simple and easy to use, quick turnaround and potential for increasing
604 community participation in future surveys, in agreement with the study in Senegal [10].
605 However, the technicians in our study were well aware of the Ov16 RDT limitations
606 concerning its inability to distinguish between past and present exposure/infection.

607 For a total of 400 individuals, the total cost per participant was estimated as US\$24 for
608 Ov16 RDT and US\$74 for skin-snip microscopy, the former being approximately a third of
609 the cost of the latter. The difference in cost between the two tests per individual (US\$50)
610 was mainly driven by differences in transport and lodging, supplies, devices and
611 instruments, labour and training. Regarding training requirements, Ov16 required a
612 relatively short time (approximated 2 hours) to train nine technicians. By contrast, skin-
613 snip microscopy training (sample-taking technique and microscopy) took 14 days. Also,
614 supplies, devices and instruments needed for skin-snip microscopy include expensive
615 instruments such as corneoscleral punches, microscopes, microtitre plates, pipettes etc.,
616 whereas those for Ov16 RDT principally include the kits from the manufacturer. Although

617 the cost of transport and lodging was considered jointly for the deployment of the two
618 tests and allocated according to the proportion of costs for each specific test and their
619 shared costs, it is important to note that if Ov16 RDT alone were used in typical
620 surveillance, fewer days would likely be necessary, making the Ov16 RDT even less costly.
621 Nevertheless, challenges with Ov16 RDT procurement must be considered when planning
622 surveillance activities.

623 **Limitations.** Our study has a number of limitations that should be addressed in future work.
624 Firstly, study participants were not randomly sampled and, therefore, study results need to
625 be interpreted with caution as they may not be truly representative of the study
626 communities. Sample sizes to ensure a given power or precision were not calculated before
627 the study; only people who agreed to gather at the focal point in their communities were
628 included in the study (convenience sampling), with only 12% of the population participating
629 overall (Table 1). This likely led to bias. Participants with clinical manifestations seeking to
630 be examined by the research team may also be those with greater levels of infection,
631 leading to overestimation of prevalence levels. Alternatively, individuals who have greater
632 adherence to treatment may also have greater willingness to participate in surveillance
633 activities, with the surveys missing a proportion of those who have higher levels of infection,
634 resulting in underestimation. Secondly, social desirability bias may have influenced the
635 results of the usability and acceptability surveys, as they were based purely on verbal
636 responses. Thirdly, the slides prepared from the incubation medium of the skin snips for
637 detection of *O. volvulus* microfilariae were not fixed and stained to assess their
638 characteristic morphological features, and no skin-snip PCR was conducted to confirm
639 species-specific identification. Therefore, we cannot totally rule out the presence of other

640 filarial species in the skin snips such as *Mansonella streptocerca* (skin-dwelling
641 microfilariae), or even *M. perstans* (blood-dwelling microfilariae that may be present in the
642 event that snips were not wholly bloodless). Fourthly, we used the Ov16 RDT with whole
643 blood, but collecting dried blood samples that are eluted in the lab and used in the RDT may
644 reach a sensitivity similar to that of the Ov16 ELISA recommended by the WHO [44].
645 However, this procedure would increase the reading time of the results to 30 minutes–24
646 hours, with the latter recommended for increased accuracy of seroprevalence estimates
647 [44,45]. Finally, as our cost estimates were calculated using specific costs for Ghana, there is
648 a need for similar implementation research in other endemic countries and settings, as
649 exemplified by the very different cost estimates presented for Senegal [10].

650 **Conclusions**

651 This study has demonstrated the usability of the Ov16 RDT to identify ongoing transmission
652 using seroprevalence in children aged 5–9 years in an area with nearly three decades of
653 CDTI, and more generally, exposure patterns in the general population. The test was also
654 more acceptable and feasible than skin-snip microscopy, less costly to implement, and may
655 help overcome the increasing reluctance of endemic communities to participate in
656 onchocerciasis surveillance activities. Regardless of these advantageous features, further
657 R&D efforts are necessary to increase the diagnostic performance of serological tests and
658 improve their ability to distinguish between past and patent infection [46]. Ideally, such
659 tests could be used to screen the population and focus on those seropositive for further
660 parasitological testing, or if it can be ensured that the measured antibody responses are
661 elicited by microfilariae and mirror their dynamics following treatment, to obviate this need
662 altogether.

663 **Abbreviations**

664 CDTI: Community Directed Treatment with Ivermectin; CI: Confidence interval; DALY:
665 Disability Adjusted Life Year; ELISA: Enzyme-Linked Immunosorbent Assay; EOT: Elimination
666 of Transmission; GBD: Global Burden of Disease; IgG: Immunoglobulin G; IgG4:
667 Immunoglobulin G4; MDA: Mass Drug Administration; NPV: Negative predictive value; NTD:
668 Neglected Tropical Disease; OCP: Onchocerciasis Control Programme in West Africa; PCR:
669 Polymerase Chain Reaction; PES: Post-Elimination Surveillance; PPV: Positive predictive
670 value; PTS: Post-Treatment Surveillance; R&D: Research and Development; REMO: Rapid
671 Epidemiological Mapping of Onchocerciasis; RDT: Rapid Diagnostic Test; SSA: Sub-Saharan
672 Africa; UI: Uncertainty interval; WHO: World Health Organization.

673 **Supporting information**

674 **S1 Text.** Interviewer guide for participants' and technicians' 'exit' interviews after
675 conducting tests.

676 **Authors' contributions**

677 **Conceptualization:** Kenneth Bentum Otabil, María-Gloria Basáñez, Henk D.F.H. Schallig,
678 Robert Colebunders.

679
680 **Data curation:** Kenneth Bentum Otabil, María-Gloria Basáñez.
681

682 **Formal analysis:** Kenneth Bentum Otabil, María-Gloria Basáñez, Lydia Datsa, Andrews
683 Agyapong Boakye, Robert Colebunders.

684
685 **Funding acquisition:** Kenneth Bentum Otabil, María-Gloria Basáñez, Henk D.F.H. Schallig
686 Robert Colebunders.

687
688 **Investigation:** Kenneth Bentum Otabil, Ameyaa Elizabeth, Michael Oppong, Prince Mensah,
689 Richmond Gyasi-Ampofo, Emmanuel John Bart-Plange, Theophilus Nti Babae, Michael
690 Tawiah Yeboah, Prince Nyarko, Prince Charles Kudzordzi, Anabel Acheampong, Edwina
691 Twum Blay.

692
693 **Methodology:** Kenneth Bentum Otabil, María-Gloria Basáñez, Henk D.F.H. Schallig, Robert
694 Colebunders.

695
696 **Project administration:** Kenneth Bentum Otabil.

697

698 **Resources:** Kenneth Bentum Otabil, María-Gloria Basáñez, Henk D.F.H. Schallig, Robert
699 Colebunders.

700

701 **Supervision:** María-Gloria Basáñez, Henk D.F.H. Schallig, Robert Colebunders.

702

703 **Visualization:** Kenneth Bentum Otabil, María-Gloria Basáñez, Lydia Datsa, Andrews
704 Agyapong Boakye.

705

706 **Writing – original draft:** Kenneth Bentum Otabil, Maria-Gloria Basáñez.

707

708 **Writing – review & editing:** Kenneth Bentum Otabil, María-Gloria Basáñez, Ameyaa
709 Elizabeth, Michael Oppong, Prince Mensah, Richmond Gyasi-Ampofo, Emmanuel John Bart-
710 Plange, Theophilus Nti Babae, Lydia Datsa, Andrews Agyapong Boakye, Michael Tawiah
711 Yeboah, Prince Nyarko, Prince Charles Kudzordzi, Anabel Acheampong, Edwina Twum Blay,
712 Henk D.F.H. Schallig, Robert Colebunders.

713

714 **Acknowledgements**

715 We thank all the staff and students of the Department of Biological Science and the Centre
716 for Research in Applied Biology who provided support in one way or another to ensure the
717 successful implementation of this research. We also appreciate the efforts of the directors
718 and staff of the Wenchi Municipal Health Directorate, Nsawkaw District and the Subinso
719 Health Centre for their enormous contributions towards the study. Our appreciation also
720 goes to the chiefs and people of the study communities who partnered with us in this study.

721 **Funding**

722 This project was supported by a small grant from the Royal Society of Tropical Medicine and
723 Hygiene, UK awarded to KBO in 2020, and from the United States Agency for International
724 Development (USAID) and UK FCDO from the British people (UK FCDO) through the Coalition
725 for Operational Research on Neglected Tropical Diseases (COR-NTD) and administered by
726 the African Research Network for Neglected Tropical Diseases (ARNTD). MGB acknowledges

727 funding from the MRC Centre for Global Infectious Disease Analysis (MRC GIDA, grant
728 number MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK-
729 funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking. RC
730 received funding from Research Foundation Flanders (FWO, grant number GOA0522N).

731 **Competing interests**

732 The authors declare that there are no competing interests regarding the publication of this
733 article.

734 **Ethical approval**

735 This study was approved by the Committee for Human Research and Ethics at the University
736 of Energy and Natural Resources, Sunyani, Ghana (approval number: CHRE/AP/012/021).
737 Written informed consent was obtained from all participants before recruitment. All
738 procedures in this study were in accordance with the ethical standards of the Helsinki
739 Declaration (1964, amended most recently in 2008) of the World Medical Association.

740 **Availability of data and materials**

741 All the data are contained in the Tables, Figures, and Supporting information.

742 **References**

- 743 1. World Health Organization. Onchocerciasis. 2022. Available from:
744 <https://www.who.int/news-room/fact-sheets/detail/onchocerciasis>.
- 745 2. Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden
746 of Disease Study 2017. Seattle, WA: IHME, 2018. Available from:
747 https://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017
748 [_Booklet.pdf](#).

- 749 3. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and
750 injuries in 204 countries and territories, 1990–2019: a systematic analysis for the
751 Global Burden of Disease Study 2019, *Lancet*. 2020;396: 1204–1222.
752 Onchocerciasis—Level 3 cause. Available from: [https://www.thelancet.com/pb-
754 assets/Lancet/gbd/summaries/diseases/onchocerciasis.pdf](https://www.thelancet.com/pb-
753 assets/Lancet/gbd/summaries/diseases/onchocerciasis.pdf).
- 754 4. Bockarie MJ, Kelly-Hope LA, Rebollo M, Molyneux DH. Preventive chemotherapy as a
755 strategy for elimination of neglected tropical parasitic diseases: endgame challenges.
756 *Philos Trans R Soc Lond B Biol Sci*. 2013;368: 20120144.
- 757 5. Mutono N, Basáñez MG, James A, Stolk WA, Makori A, Kimani TN, et al. Elimination
758 of transmission of onchocerciasis (river blindness) with long-term ivermectin mass
759 drug administration with or without vector control in sub-Saharan Africa: a
760 systematic review and meta-analysis. *Lancet Glob Health*. 2024;12: e771-e782.
- 761 6. World Health Organization. Ending the neglect to attain the Sustainable
762 Development Goals: a road map for neglected tropical diseases 2021–2030.
763 Available from: <https://www.who.int/publications/i/item/9789240010352>.
- 764 7. Lakwo T, Oguttu D, Ukety T, Post R, Bakajika D. Onchocerciasis elimination: progress
765 and challenges. *Res Rep Trop Med*. 2020;11: 81–95.
- 766 8. Taylor HR, Munoz B, Keyvan-Larijani E, Greene BM. Reliability of detection of
767 microfilariae in skin snips in the diagnosis of onchocerciasis. *Am J Trop Med Hyg*.
768 1989;41: 467–471.
- 769 9. Bottomley C, Isham V, Vivas-Martínez S, Kuesel AC, Attah SK, Opoku NO, et al.
770 Modelling Neglected Tropical Diseases diagnostics: the sensitivity of skin snips for
771 *Onchocerca volvulus* in near elimination and surveillance settings. *Parasit Vectors*.
772 2016;9: 343.
- 773 10. Dieye Y, Storey HL, Barrett KL, Gerth-Guyette E, Di Giorgio L, Golden A, et al.
774 Feasibility of utilizing the SD BIOLINE Onchocerciasis IgG4 rapid test in onchocerciasis
775 surveillance in Senegal. *PLoS Negl Trop Dis*. 2017;11: e0005884.
- 776 11. Abong RA, Amambo GN, Chounna Ndongmo PW, Njouendou AJ, Ritter M, Beng AA,
777 et al. Differential susceptibility of *Onchocerca volvulus* microfilaria to ivermectin in
778 two areas of contrasting history of mass drug administration in Cameroon: relevance
779 of microscopy and molecular techniques for the monitoring of skin microfilarial
780 repopulation within six months of direct observed treatment. *BMC Infect Dis*.
781 2020;20: 726.
- 782 12. Lobos E, Weiss N, Karam M, Taylor HR, Ottesen EA, Nutman TB. An immunogenic
783 *Onchocerca volvulus* antigen: a specific and early marker of infection. *Science*.
784 1991;251: 1603-1605.
- 785 13. Cama VA, McDonald C, Arcury-Quandt A, Eberhard M, Jenks MH, Smith J, et al.
786 Evaluation of an OV-16 IgG4 Enzyme-Linked Immunosorbent Assay in humans and its
787 application to determine the dynamics of antibody responses in a non-human
788 primate model of *Onchocerca volvulus* infection. *Am J Trop Med Hyg*. 2018;99: 1041–
789 1048.

- 790 14. Lont YL, Coffeng LE, de Vlas SJ, Golden A, de Los Santos T, Domingo GJ, et al.
791 Modelling anti-Ov16 IgG4 antibody prevalence as an indicator for evaluation and
792 decision making in onchocerciasis elimination programmes. *PLoS Negl Trop Dis*.
793 2017;11: e0005314.
- 794 15. Golden A, Stevens EJ, Yokobe L, Faulx D, Kalnoky M, Peck R, et al. A recombinant
795 positive control for serology diagnostic tests supporting elimination of *Onchocerca*
796 *volvulus*. *PLoS Negl Trop Dis*. 2016;10: e0004292.
- 797 16. Vlaminck J, Fischer PU, Weil GJ. Diagnostic tools for onchocerciasis elimination
798 programs. *Trends Parasitol*. 2015;31: 571–582.
- 799 17. Biritwum NK, de Souza DK, Asiedu O, Marfo B, Amazigo UV, Gyapong JO.
800 Onchocerciasis control in Ghana (1974-2016). *Parasit Vectors*. 2021;14: 3.
- 801 18. Ghana Health Service. Ghana NTD Master Plan 2016–2020. Expanded Special Project
802 for Elimination of Neglected Tropical Diseases. 2020. Available from:
803 https://espen.afro.who.int/system/files/content/resources/GHANA_NTD_Master_Plan_2016_2020.pdf.
804
- 805 19. Otabil KB, Basáñez MG, Ankrah B, Opoku SA, Kyei DO, Hagan R, et al. Persistence of
806 onchocerciasis and associated dermatologic and ophthalmic pathologies after
807 27 years of ivermectin mass drug administration in the middle belt of Ghana. *Trop*
808 *Med Int Health*. 2023;28: 844–854.
- 809 20. Otabil KB, Ankrah B, Bart-Plange EJ, Donkoh ES, Avarikame FA, Ofori-Appiah FO, et al.
810 Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27
811 years of mass drug administration with ivermectin. *Infect Dis Poverty*. 2023;12: 75.
- 812 21. Otabil KB, Basáñez MG, Ankrah B, Bart-Plange EJ, Babae TN, Kudzordzi PC, et al. Non-
813 adherence to ivermectin in onchocerciasis-endemic communities with persistent
814 infection in the Bono Region of Ghana: a mixed methods study. *BMC Infect Dis*.
815 2023;23: 805.
- 816 22. Kura K, Milton P, Hamley JID, Walker M, Bakajika DK, Kanza EM, et al. Can mass drug
817 administration of moxidectin accelerate onchocerciasis elimination in Africa? *Philos*
818 *Trans R Soc Lond B Biol Sci*. 2023;378: 20220277.
- 819 23. Hutubessy R, Chisholm D, Tan-Torres Edejer T. Generalized cost-effectiveness
820 analysis for national-level priority-setting in the health sector. *Cost Eff Resour Alloc*.
821 2003;1: 8.
- 822 24. Bland M. *An Introduction to Medical Statistics*. Oxford: Oxford University Press;
823 1991.
- 824 25. Cicchetti DV, Feinstein AR. High agreement but low kappa: II. resolving the
825 paradoxes. *J Clin Epidemiol*. 1990;43: 551–558.
- 826 26. Hazra A, Gogtay N. *Biostatistics Series Module 7: the statistics of diagnostic tests*.
827 *Indian J Dermatol*. 2017;62: 18–24.
- 828 27. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. *Stat Sci*.
829 2001;16: 101–117.

- 830 28. World Health Organization & African Programme for Onchocerciasis Control.
831 Guidelines for revising ivermectin treatment boundaries within the context of
832 onchocerciasis elimination. African Programme for Onchocerciasis Control. 2015.
833 Available from: <https://apps.who.int/iris/handle/10665/343029>.
- 834 29. Eneanya OA, Koudou BG, Aboulaye M, Elvis AA, Souleymane Y, Kouakou MM, et al.
835 Progress towards onchocerciasis elimination in Côte d'Ivoire: a geospatial modelling
836 study. PLoS Negl Trop Dis. 2021;15: e0009091.
- 837 30. Nyagang SM, Cumber SN, Cho JF, Keka EI, Nkfusai CN, Wepngong E, et al. Prevalence
838 of onchocerciasis, attitudes and practices and the treatment coverage after 15 years
839 of mass drug administration with ivermectin in the Tombel Health District,
840 Cameroon. Pan Afr Med J. 2020;35: 107.
- 841 31. Kifle B, Woldemichael K, Nigatu M. Prevalence of onchocerciasis and associated
842 factors among adults aged ≥ 15 years in Semen Bench District, Bench Maji Zone,
843 Southwest Ethiopia: community based cross-sectional study. Adv Publ Health.
844 2019;2019: 7276230.
- 845 32. Willen L, Basáñez MG, Dvorak V, Veriegh FBD, Aboagye FT, Idun B, et al. Human
846 immune response against salivary antigens of *Simulium damnosum* s.l.: a new
847 epidemiological marker for exposure to blackfly bites in onchocerciasis endemic
848 areas. PLoS Negl Trop Dis. 2021;15: e0009512.
- 849 33. Willen L, Milton P, Hamley JID, Walker M, Osei-Atweneboana MY, Volf P, et al.
850 Demographic patterns of human antibody levels to *Simulium damnosum* s.l. saliva in
851 onchocerciasis-endemic areas: an indicator of exposure to vector bites. PLoS Negl
852 Trop Dis. 2022;16: e0010108.
- 853 34. Prost A. [Latency period in onchocerciasis]. Bull World Health Organ. 1980;58: 923–
854 925 (article in French).
- 855 35. World Health Organization. Guidelines for stopping mass drug administration and
856 verifying elimination of human onchocerciasis. Criteria and procedures. 2016.
857 Available from: <https://www.who.int/publications/i/item/9789241510011>.
- 858 36. Hamley JID, Walker M, Coffeng LE, Milton P, de Vlas SJ, Stolk WA, et al. Structural
859 uncertainty in onchocerciasis transmission models influences the estimation of
860 elimination thresholds and selection of age groups for seromonitoring. J Infect Dis.
861 2020;221(Suppl 5): S510–S518.
- 862 37. Dolo H, Coulibaly YI, Sow M, Dembélé M, Doumbia SS, Coulibaly SY, et al. Serological
863 evaluation of onchocerciasis and lymphatic filariasis elimination in the Bakoye and
864 Falémé Foci, Mali. Clin Infect Dis. 2021;72: 1585–1593.
- 865 38. Paulin HN, Nshala A, Kalinga A, Mwingira U, Wiegand R, Cama V, et al. Evaluation of
866 onchocerciasis transmission in Tanzania: preliminary rapid field results in the Tukuyu
867 focus, 2015. Am J Trop Med Hyg. 2017;97: 673–676.
- 868 39. Mshana MI, Silvestri V, Mushi V, Bonaventura WM, Tarimo D, Ngasala B, et al.
869 Burden and factors associated with onchocerciasis transmission among school-aged
870 children after more than 20 years of Community Directed Treatment with Ivermectin
871 in Ulanga district, Tanzania: a school-based cross-sectional study. PLoS Glob Public
872 Health. 2023;3: e0001919.

- 873 40. Siewe Fodjo JN, Tatah G, Tabah EN, Ngarka L, Nfor LN, Chokote SE, et al.
874 Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river
875 valleys of Cameroon: impact of more than 13 years of ivermectin. *Infect Dis Poverty*.
876 2018;7: 114.
- 877 41. Barbazan P, Escaffre H, Mbentengam R, Boussinesq M. [Entomologic study on the
878 transmission of onchocerciasis in a forest-savanna transition area of Cameroon]. *Bull*
879 *Soc Pathol Exot*. 1998;91: 178–182 (article in French).
- 880 42. Siewe Fodjo JN, Vieri MK, Ngarka L, Njamnshi WY, Nfor LN, Mengnjo MK, et al. 'Slash
881 and clear' vector control for onchocerciasis elimination and epilepsy prevention: a
882 protocol of a cluster randomised trial in Cameroonian villages. *BMJ Open*. 2021;11:
883 e050341.
- 884 43. Otabil KB, Gyasi SF, Awuah E, Obeng-Ofori D, Tenkorang SB, Kessie JA, et al. Biting
885 rates and relative abundance of *Simulium* flies under different climatic conditions in
886 an onchocerciasis endemic community in Ghana. *Parasit Vectors*. 2020;13: 229.
- 887 44. Nana-Djeunga HC, Sicard CM, Mogoung-Wafo AE, Chesnais CB, Deléglise H, Touka-
888 Nounkeu R, et al. Changes in onchocerciasis Ov16 IgG4 rapid diagnostic test results
889 over one-month follow-up: lessons for reading timeframe and decision-making. *Am J*
890 *Trop Med Hyg*. 2022;107: 658–661.
- 891 45. Peck RB, Golden AL. Assay of dried blood spots using the SD BIOLINE Onchocerciasis
892 IgG4 Rapid Test. Seattle, WA USA: PATH; 2019. Available from:
893 [https://www.path.org/our-impact/resources/assay-dried-blood-spots-using-sd-](https://www.path.org/our-impact/resources/assay-dried-blood-spots-using-sd-bioline-onchocerciasis-igg4-rapid-test/)
894 [bioline-onchocerciasis-igg4-rapid-test/](https://www.path.org/our-impact/resources/assay-dried-blood-spots-using-sd-bioline-onchocerciasis-igg4-rapid-test/).
- 895 46. Bennuru S, Oduro-Boateng G, Osigwe C, Del Valle P, Golden A, Ogawa GM, et al.
896 Integrating multiple biomarkers to increase sensitivity for the detection of
897 *Onchocerca volvulus* infection. *J Infect Dis*. 2020;221: 1805–1815.